-
This report used data derived and validated from completed randomized phase III trials to demonstrate that an AI-based predictive model could identify pts with predominately intermediate-risk #ProstateCancer who are likely to benefit from short-term androgen deprivation therapy.
— NEJM Evidence (@NEJMEvidence) June 29, 2023 -
In NEJM, DeBoy, Armanios, et al. describe an association between germline mutations in POT1, encoding the protection of telomeres 1 protein, and the development of clonal hematopoiesis. Full article: https://t.co/4CjTpmZXLv
— NEJM (@NEJM) June 29, 2023
Science behind the Study: https://t.co/2XWd8z7vM2 1/11 pic.twitter.com/nOIOGi2wpu -
Thursday 8am HIV teaching sessions are a wrap for 2022-23 academic year!
— Paul Sax (@PaulSaxMD) June 29, 2023
In other words, see you later to M184V, K103N, E138K, K65R, M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R, Q148H, and the rest of the gang pic.twitter.com/z3GUq89B7X -
A 64-year-old man who reported current use of tobacco presented with a 2-week history of tongue discoloration. He reported no associated dysgeusia or tongue pain. 1/3 pic.twitter.com/ecPIYa6zDb
— NEJM (@NEJM) June 29, 2023 -
Dr. Roma Bhatia shares how being an NEJM editorial fellow was a worthwhile experience and helped her determine the next step in her career. Applications for the 2024–25 editorial fellowship are now open. For more information, visit https://t.co/Mte8IOIzK7. pic.twitter.com/2skvRXhLw3
— NEJM (@NEJM) June 29, 2023
Infectious Diseases